Posted by Michael Wonder on 04 Dec 2017
Brand name drug sales soar in Canada, while R&D sags
1 December 2017 - Patented drug industry disputes it's failing to invest enough into research and development.
Canada's manufacturers of brand name medicines have once again fallen far short of a promise to invest 10 per cent of their annual sales into research and development.
According to a report by the Patented Medicine Prices Review Board, sales of brand name drugs hit a record $20 billion in 2016, yet makers of those drugs invested just $918 million in R&D, or 4.4% of total sales.
